News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SALVAT Files NDA For Its CETRAXAL Otic -Ciprofloxacin Otic- 0.2% Solution, For The Treatment Of External Otitis


10/19/2005 5:08:54 PM

BARCELONA, Spain, June 10 /PRNewswire/ -- SALVAT today announced that it has submitted a new drug application for their CETRAXAL Otic solution, with its convenient, single-dispensing container (SDC) format, with the FDA.

The efficacy and safety of the treatment has been assessed in a 630 patient phase III clinical trial, which is the basis for their application.

"We combined the advantages of a proven, effective antibiotic with a simple, accurate form of administration. The idea behind our product is to reduce unnecessary ingredients thus avoiding unexpected adverse reactions, especially problematic in the pediatric population.

We are convinced that finding the right commercial partner in the US will help us to bring the benefits of this new product to a great number of patients" said Jordi Julve, COO of SALVAT.

About SALVAT

SALVAT is an independent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D.

CONTACT: Dietmar Jannaschk, e-mail: djk@salvat-lab.es

LABORATORIOS SALVAT

CONTACT: Dietmar Jannaschk, e-mail: djk@salvat-lab.es


Read at BioSpace.com


comments powered by Disqus
   
Otitis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES